Pharmacogenomics of Human Drug Transporters: Clinical Impacts

Description

Sets the foundation for safer, more effective drug therapiesWith this book as their guide, readers will discover how to apply our current understanding of the pharmacogenomics of drug transporters to advance their own drug discovery and development efforts. In particular, the book explains how new findings in the field now enable researchers to more accurately predict drug interactions and adverse drug reactions. Moreover, it sets the foundation for the development of drug therapies that are tailored to an individual patient's genetics. Pharmacogenomics of Human Drug Transporters serves as a comprehensive guide to how transporters regulate the absorption, distribution, and elimination of drugs in the body as well as how an individual's genome affects those processes. The book's eighteen chapters have been authored by a team of leading pioneers in the field. Based on their own laboratory and clinical experience as well as a thorough review of the literature, these authors explore all facets of drug transporter pharmacogenomics, including: Individual drug transporters and transporter families and their clinical significancePrinciples of altered drug transport in drug?drug interactions, pharmacotherapy, and personalized medicineEmerging new technologies for rapid detection of genetic polymorphismsClinical aspects of genetic polymorphisms in major drug transporter genesFuture research directions of drug transporter pharmacogenomics and the prospect of individualized medicinePharmacogenomics of Human Drug Transporters opens the door to new drug discovery and development breakthroughs leading to safer and more effective customized drug therapies.The book is recommended for pharmaceutical scientists, biochemists, pharmacologists, clinicians, and genetics and genomics researchers.Content: Chapter 1 Introduction to Pharmacogenomics of Drug Transporters (pages 1–11): Marianne K. DeGorter and Richard B. KimChapter 2 ADME Pharmacogenomics in Drug Development (pages 13–37): Liangfu Chen and Joseph W. PolliChapter 3 Regulatory Perspective on Pharmacogenomics of Drug?Metabolizing Enzymes and Transporters (pages 39–71): Lei Zhang, Gilbert J. Burckart, Lawrence J. Lesko and Shiew?Mei HuangChapter 4 The Pharmacogenomics of Membrane Transporters Project (pages 73–108): Sook Wah Yee, Deanna L. Kroetz and Kathleen M. GiacominiChapter 5 Emerging New Technology of SNP Typing (pages 109–124): Toshihisa Ishikawa and Yoshihide HayashizakiChapter 6 OATP1A2, OAT1, and OAT3 (pages 125–139): Rommel G. TironaChapter 7 OATP1B1, OATP1B3, and OATP2B1 (pages 141–169): Jorg Konig and Martin F. FrommChapter 8 OCT (SLC22A) and OCTN Family (pages 171–208): Sophie L. Stocker, Arian Emami Riedmaier, Matthias Schwab and Kathleen M. GiacominiChapter 9 MATE (SLC47) Family (pages 209–222): Atsushi Yonezawa and Ken?ichi InuiChapter 10 PEPT (SLC15A) Family (pages 223–242): Tomoko Sugiura, Saki Umeda, Akira Tsuji and Yukio KatoChapter 11 Nucleoside Transporters (SLC28 and SLC29) Family (pages 243–270): Miriam Molina?Arcas and Marcal Pastor?AngladaChapter 12 P?glycoprotein (MDR1/ABCB1) (pages 271–293): Ingolf CascorbiChapter 13 BSEP (ABCB11) (pages 295–309): Bruno Stieger and Gerd A. Kullak?UblickChapter 14 BCRP (ABCG2) (pages 311–343): Agnes Basseville, Susan E. Bates, William D. Figg and Alex SparreboomChapter 15 MRP2 (ABCC2) and MRP3 (ABCC3) (pages 345–364): Anne T. NiesChapter 16 MRP4 (ABCC4) (pages 365–385): Satish B. Cheepala, Mugdha Sukthankar and John D. SchuetzChapter 17 MRP8 (ABCC11) (pages 387–400): Yu Toyoda and Toshihisa IshikawaChapter 18 Future Perspectives (pages 401–416): Toshihisa Ishikawa and Joseph Ware